Cue Health Inc.

NasdaqCM:HLTH Stock Report

Market Cap: US$14.7m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Cue Health Valuation

Is HLTH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HLTH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HLTH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HLTH's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HLTH?

Key metric: As HLTH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HLTH. This is calculated by dividing HLTH's market cap by their current revenue.
What is HLTH's PS Ratio?
PS Ratio0.2x
SalesUS$70.94m
Market CapUS$14.72m

Price to Sales Ratio vs Peers

How does HLTH's PS Ratio compare to its peers?

The above table shows the PS ratio for HLTH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.6x
ADGM Adagio Medical Holdings
20.7xn/aUS$11.3m
SSKN STRATA Skin Sciences
0.4x9.6%US$12.1m
SCND Scientific Industries
1xn/aUS$10.7m
VASO Vaso
0.3xn/aUS$24.3m
HLTH Cue Health
0.2x38.4%US$14.7m

Price-To-Sales vs Peers: HLTH is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (2.9x).

Price to Sales Ratio vs Industry

How does HLTH's PS Ratio compare vs other companies in the US Medical Equipment Industry?

48 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.3.5x8.2%
HLTH Cue Health
 0.2x38.4%US$14.72m
VREX Varex Imaging
0.7x2.3%US$557.44m
INGN Inogen
0.8x4.4%US$249.38m
HLTH 0.2xIndustry Avg. 3.5xNo. of Companies48PS03.26.49.612.816+
48 CompaniesEstimated GrowthMarket Cap
Industry Avg.3.5x16.6%
HLTH Cue Health
 0.2x51.0%US$14.72m
No more companies

Price-To-Sales vs Industry: HLTH is good value based on its Price-To-Sales Ratio (0.2x) compared to the US Medical Equipment industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is HLTH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HLTH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.2x
Fair PS Ratio0.0005x

Price-To-Sales vs Fair Ratio: HLTH is expensive based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HLTH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.000001
US$0.75
+74,999,900.0%
33.3%US$1.00US$0.50n/a2
Jan ’26US$0.000001
US$0.75
+74,999,900.0%
33.3%US$1.00US$0.50n/a2
Dec ’25US$0.0001
US$0.75
+749,900.0%
33.3%US$1.00US$0.50n/a2
Nov ’25US$0.000001
US$0.75
+74,999,900.0%
33.3%US$1.00US$0.50n/a2
Oct ’25US$0.000001
US$0.75
+74,999,900.0%
33.3%US$1.00US$0.50n/a2
Sep ’25US$0.0001
US$0.75
+749,900.0%
33.3%US$1.00US$0.50n/a2
Aug ’25US$0.0001
US$0.75
+749,900.0%
33.3%US$1.00US$0.50n/a2
Jul ’25US$0.0055
US$0.75
+13,536.4%
33.3%US$1.00US$0.50n/a2
Jun ’25US$0.068
US$0.75
+1,009.5%
33.3%US$1.00US$0.50n/a2
May ’25US$0.14
US$0.75
+455.6%
33.3%US$1.00US$0.50n/a2
Apr ’25US$0.18
US$0.83
+350.4%
28.3%US$1.00US$0.50n/a3
Mar ’25US$0.27
US$1.05
+296.1%
48.6%US$2.00US$0.50n/a5
Feb ’25US$0.22
US$1.05
+368.8%
48.6%US$2.00US$0.50n/a5
Jan ’25US$0.16
US$2.60
+1,500.0%
105.6%US$8.00US$0.50US$0.0000015
Dec ’24US$0.32
US$2.60
+720.2%
105.6%US$8.00US$0.50US$0.00015
Nov ’24US$0.30
US$3.35
+1,016.7%
82.8%US$8.00US$0.75US$0.0000015
Oct ’24US$0.44
US$3.94
+790.2%
71.3%US$8.00US$0.75US$0.0000014
Sep ’24US$0.51
US$3.94
+669.2%
71.3%US$8.00US$0.75US$0.00014
Aug ’24US$0.46
US$4.19
+818.5%
63.7%US$8.00US$0.75US$0.00014
Jul ’24US$0.37
US$4.19
+1,034.8%
63.7%US$8.00US$0.75US$0.00554
Jun ’24US$0.71
US$4.69
+555.8%
44.8%US$8.00US$2.75US$0.0684
May ’24US$0.77
US$5.25
+585.6%
34.0%US$8.00US$3.00US$0.144
Apr ’24US$1.82
US$5.38
+195.3%
30.4%US$8.00US$3.50US$0.184
Mar ’24US$2.06
US$6.25
+203.4%
23.7%US$8.00US$4.00US$0.274
Feb ’24US$2.49
US$6.25
+151.0%
23.7%US$8.00US$4.00US$0.224
Jan ’24US$2.07
US$6.50
+214.0%
23.1%US$8.00US$4.00US$0.164
Analyst Price Target
Consensus Narrative from 2 Analysts
US$0.75
Fair Value
87.9% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/28 09:56
End of Day Share Price 2024/05/28 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cue Health Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Mark MassaroBTIG
Matthew SykesGoldman Sachs